Selective oestrogen receptor modulators: a new paradigm for HRT
- 1 June 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 10 (3), 189-192
- https://doi.org/10.1097/00001703-199806000-00002
Abstract
Selective oestrogen receptor modulators are a range of compounds which mimic some, but not all, agonist actions of oestrogen in different tissues. They were developed with the aim of maximizing the benefits of oestrogen-like drugs in a number of important conditions whilst reducing adverse side-effects. The molecular biology of oestrogen receptor signalling is discussed in relation to the pharmacological effects of this class of drugs. The results of clinical trial data with one member of this group (raloxifene) are documented and future developments outlined.Keywords
This publication has 30 references indexed in Scilit:
- Estrogen replacement therapy and longitudinal decline in visual memoryNeurology, 1997
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's diseaseNeurology, 1997
- Effect of oestrogen during menopause on risk and age at onset of Alzheimer's diseaseThe Lancet, 1996
- The Use of Estrogens and Progestins and the Risk of Breast Cancer in Postmenopausal WomenNew England Journal of Medicine, 1995
- Estrogen Deficiency and Risk of Alzheimer's Disease in WomenAmerican Journal of Epidemiology, 1994
- Postmenopausal Estrogen Therapy and Cardiovascular DiseaseNew England Journal of Medicine, 1991
- Estrogen and coronary heart disease in womenPublished by American Medical Association (AMA) ,1991
- Reduction of cardiovascular disease—related mortality among postmenopausal women who use hormones: Evidence from a national cohortAmerican Journal of Obstetrics and Gynecology, 1991
- BONE RESPONSE TO TERMINATION OF ŒSTROGEN TREATMENTThe Lancet, 1978